Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
On September 14, 2026, Piramal Pharma disclosed that its Morpeth facility in the UK received 7 observations from the US FDA following an inspection conducted between September 3-11, 2026. The company stated it would respond to these observations.
As of 13:19 IST on September 17, 2026, Piramal Pharma was trading at ₹202.53, down 0.46% for the day. In the past year, the stock has lost value compared to a 8.14% gain in the NIFTY and a 17.48% loss in the Nifty Pharma index.
Piramal Pharma's Sustainability Report for the financial year 2025-26, released on August 24, 2026, highlighted a 22.6% reduction in Scope 1 and 2 GHG emissions against the FY2022 baseline. The company also reported spending ₹8.98 Crore on CSR projects that impacted approximately 1.8 million people.
As of the trading day ending September 17, 2026, the daily trend for Piramal Pharma shows a 'bearish' Supertrend direction with the closing price at ₹204.71, below the 20-day Exponential Moving Average (EMA) of ₹210.48. However, the weekly trend indicates a 'bullish' Supertrend direction, with the closing price above the 20-day EMA of ₹191.60.
As of 18 Sept 2026, 03:30 pm
Recent drawdown or price variability is high enough to warrant closer monitoring.
Primary driver: Price remains materially below a previous peak
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹2,269.92 crore | PEAK₹2,751.77 crore | ₹2,139.87 crore | ₹2,043.72 crore | ₹1,933.71 crore |
| Income | ₹2,359.33 crore | PEAK₹2,797.83 crore | ₹2,183.11 crore | ₹2,109.32 crore | ₹1,992.11 crore |
| Expenses | ₹2,386.35 crore | PEAK₹2,592.63 crore | ₹2,246.12 crore | ₹2,170.29 crore | ₹2,110.44 crore |
| Finance Costs | ₹88.08 crore | ₹82.99 crore | PEAK₹89.24 crore | ₹82.42 crore | ₹86.15 crore |
| Other Expenses | ₹546.82 crore | PEAK₹649.57 crore | ₹557.98 crore | ₹571.07 crore | ₹514.37 crore |
| Profit Before Exceptional Items And Tax | -₹27.02 crore | PEAK₹205.20 crore | -₹63.01 crore | -₹60.97 crore | -₹118.33 crore |
Exchange disclosures and regulatory announcements for Piramal Pharma.
Disclosure under Regulation 30 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015 ESG Rating |SUBJECT: General Updates
Disclosure under Regulation 30 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015 FDA Inspection |SUBJECT: General Updates
Piramal Pharma Limited announced two institutional investor meetings scheduled for September 29 and 30, 2026, at 13:30 in the United Kingdom. Organized by Avendus Spark Institutional Equities, both events will be physical group meetings focused on providing a general update to multiple investors. Gagan Borana is designated as the contact person for these engagements.
Piramal Pharma Limited informed stock exchanges on September 8, 2026, that it will hold physical one-on-one institutional investor meetings in the United Kingdom on September 29 and 30, 2026, arranged by Avendus Spark Institutional Equities Group, with dates subject to change.
NAME(S)OF THE ACQUIRER AND ITS(PAC) : Deutsche Bank AG, Mumbai Branch
Piramal Pharma Limited submitted its Sustainability Report for the financial year 2025-26 to the BSE and NSE on August 24, 2026. The report covers non-financial performance from April 1, 2025, to March 31, 2026, across three business units: Piramal Pharma Solutions, Piramal Critical Care, and Piramal Consumer Healthcare. Key disclosed outcomes include a 22.6% reduction in Scope 1 and 2 GHG emissions compared to the FY2022 baseline, ₹8.98 Crore spent on CSR projects impacting approximately 1.8 million people, and an external assurance provided by DNV Business Assurance India Pvt Ltd.
NAME(S)OF THE ACQUIRER AND ITS(PAC) : Deutsche Bank AG, Mumbai Branch acting in its capacity as the onshore security agent for Lenders
On August 18, 2026, Piramal Pharma Limited completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited for approximately ₹76 crores, increasing its total shareholding from 33.33% to 74.00%. This transaction converted Yapan from an associate company into a subsidiary and involved the purchase of 1,46,400 equity shares at ₹10 each. The acquisition integrates Yapan's large molecule capabilities into Piramal Pharma's offerings, following Yapan's reported revenues of ₹26.91 crores, ₹54.40 crores, and ₹26.34 crores for fiscal years 2024, 2025, and 2026 respectively.
Recent market and company developments associated with Piramal Pharma.
Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site
Piramal Pharma Ltd is quoting at Rs 202.53, down 0.46% on the day as on 13:19 IST on the NSE. The stock in last one year as compared to a 8.14% in NIFTY and a 17.48% lost in the Nifty Pharma index.
The USFDA issued a Form 483 following a Good Manufacturing Practices (GMP) inspection of the facility, Piramal Pharma said in a stock exchange filing on Monday.
Piramal Pharma’s Morpeth facility in the UK received 7 US FDA observations after an inspection from September 3-11, 2026. The company will respond.
Shares of Piramal Pharma Ltd ended at ₹211.90, down by ₹0.60, or 0.28%, on the BSE.
Piramal Pharma, Piramal Pharma stock outlook, Piramal Pharma share price, Rakesh Vyas, Quest Investment Managers, CDMO stocks India, pharma stocks India, Piramal Pharma EBITDA growth, Piramal Pharma earnings recovery, destocking impact pharma, contract development and manufacturing, Indian pharma sector outlook, CDMO business growth, Piramal Pharma all-time high, healthcare stocks India, pharma market analysis, operating leverage in pharma, midcap pharma stocks, Indian stock market pharma picks, Business Today pharma news
Stock market today: Indian stock market indices Sensex and Nifty 50 are set for a lower open on 8 September amid mixed global cues. Nifty 50 closed below 23,800, signaling bearish momentum, while elevated crude oil prices and geopolitical tensions raise concerns over inflation and market sentiment.
In the past month, Sai Life Science stock surged 19 per cent, against a 2.8 per cent decline in the BSE Sensex.
Comprehensive Section Breakdown for Piramal Pharma
Piramal Pharma Limited reported a 17.4% increase in revenue from operations to ₹2,269.9 crore for the quarter ended 30 June 2026. The company’s net loss narrowed compared with the same quarter a year ago, as expenses grew at a slower pace than revenue. The quarter recorded no exceptional items, following a gain in the prior-year quarter and a significant charge in the preceding March quarter.
Revenue from operations was ₹2,269.92 crore, up 17.4% from ₹1,933.71 crore in the first quarter of the previous year. Sequentially, revenue declined 17.5% from ₹2,751.77 crore in the March 2026 quarter. Including other income of ₹89.41 crore, total income reached ₹2,359.33 crore, an 18.4% increase year-on-year.
Total expenses rose 13.1% to ₹2,386.35 crore, a slower rate than revenue growth. Key expense components for the quarter were:
The slower expense growth relative to revenue indicates operating leverage.
Profit before exceptional items and tax improved to a loss of ₹27.02 crore, compared with a loss of ₹118.33 crore a year ago. After accounting for exceptional items (nil this quarter versus a gain of ₹20.74 crore in the prior-year quarter), profit before tax narrowed to a loss of ₹27.02 crore (last year: loss of ₹97.59 crore).
Operating profit before interest, tax, depreciation and amortisation (EBITDA) was approximately ₹284.6 crore, yielding an EBITDA margin of 12.5% on revenue from operations.
Exceptional items before tax were absent this quarter, contrasting with a gain of ₹20.74 crore in the same quarter last year and a substantial charge of ₹175.77 crore in the immediately preceding quarter (Q4 FY2025-26).
Tax expense rose sharply to ₹61.93 crore from ₹2.68 crore a year earlier. This increase widened the net loss from continuing operations to ₹88.95 crore, compared with ₹100.27 crore in the prior-year quarter. After including a share of profit from associates of ₹19.56 crore, the overall net loss for the period was ₹69.39 crore, compared with ₹81.70 crore last year.
Comprehensive income for the period was a loss of ₹99.94 crore, compared with a loss of ₹37.56 crore last year. The widening comprehensive loss was driven by other comprehensive income swinging from a gain of ₹44.14 crore a year ago to a loss of ₹30.55 crore in the current quarter.
Basic and diluted earnings per share from continuing operations was -₹0.52 per share, compared with -₹0.62 per share last year. There were no discontinued operations.
Piramal Pharma reported a strong Q1FY27 with consolidated revenue from operations rising 17% YoY to ₹2,270 crore, driven by healthy performance across all three businesses. EBITDA surged 72% to ₹285 crore, with margin expanding approximately 400 basis points to 12.5%, reflecting improved capacity utilization, pricing discipline, and operational excellence. Management, led by Chairperson Nandini Piramal, expressed confidence in sustaining revenue growth and significant profitability expansion through FY27, while remaining agile amid dynamic external conditions.
The CDMO segment delivered 19% YoY revenue growth, supported by broad-based performance across sites, an enhanced commercial team, and favorable tailwinds from increased biopharma funding and supply-chain diversification. However, management cautioned that customer decision-making timelines remain prolonged and emphasized that converting the strong RFP pipeline into orders is a key growth driver. The Complex Hospital Generics (CHG) business grew 17%, maintaining leadership in core therapies like US Sevoflurane and intrathecal Baclofen, with Kenalog® integration on track for supplies from Q2FY27. The Consumer Healthcare (PCH) business posted 15% growth, powered by Power Brands (+23%) and e-commerce (+40%), while premiumization and cost initiatives helped offset raw material inflation.
Piramal Pharma’s first quarter of FY2026-27 showed a clear improvement in underlying operating results. Revenue grew 17.4% while expenses rose at a slower 13.1% rate, narrowing the pre-tax loss. EBITDA turned positive at ₹284.6 crore, reflecting a 12.5% margin on revenue. The net loss of ₹69.4 crore was smaller than last year’s ₹81.7 crore, though a sharp increase in tax expense to ₹61.9 crore limited the bottom-line improvement. The absence of exceptional items also simplified the profit comparison.
Strategic Vision: Global pharmaceutical company advancing healthcare through products and services.
Category: B2B Services
Piramal Pharma Solutions operates as a Contract Development and Manufacturing Organization (CDMO) providing end-to-end development and manufacturing solutions across the drug lifecycle.
Category: Supply Chain
Piramal Critical Care is a global provider of inhaled anesthetics and hospital generics, focusing on delivering critical care products to healthcare systems.
Category: Consumer Goods
Piramal Consumer Healthcare is a significant player in the Indian self-care market, offering a portfolio of branded consumer healthcare and wellness products.
Key Products & Services: Littles • Lacto Calamine • i-pill • Tetmosol • Polycrol • Tri-Activ • Sloan's • Nixit
Category: Joint Venture
This joint venture is active in the ophthalmic category in India, providing medications and devices for various eye conditions.
Core Thesis: The company operates through distinct business segments that cater to different aspects of the pharmaceutical and healthcare value chain, from development and manufacturing to critical care and consumer health.
• Integrated Services: Piramal Pharma Solutions offers end-to-end development and manufacturing services across the drug lifecycle, supporting pharmaceutical, biotech, and academic sectors. • Global Reach: The company maintains a global presence with facilities and distribution networks spanning North America, Europe, Asia, and over 100 countries worldwide. • Specialized Offerings: Piramal Pharma focuses on specialized areas such as critical care products, consumer healthcare, and ophthalmic solutions through its various business units.
• Globally integrated network of facilities
• Science-led innovation
• Adherence to global quality and regulatory standards
• Diverse portfolio of products and services